Butler and colleagues (62) reported that the combination treatment with anti–PD-L1 and anti-LAG3 mAb during established malaria enhances TFh responses, plasma cell formation, and protective antibody generation in a mouse model of malaria. The gene discussed is LAG3; the disease is malaria.